UH3AR076729
Cooperative Agreement
Overview
Grant Description
The Spine Phenome Project: Enabling Technology for Personalized Medicine - Project Summary/Abstract
Chronic low back pain (CLBP) is a debilitating condition that affects millions of people globally. Despite increased utilization of interventions and rising medical costs, CLBP prevalence has continued to increase. This problem arises because CLBP is complex, heterogeneous, and current diagnostics and treatments rely primarily on subjective metrics and do not target all the multidimensional biopsychosocial mechanisms associated with CLBP.
Specifically, most diagnostics do not quantitatively consider patient functional measures. This multidisciplinary effort proposes to address this problem by developing and validating a digital health platform and provide meaningful data-driven metrics that enable an integrated approach to clinical evaluation and treatment of CLBP. This platform will facilitate the use of quantitative spinal motion metrics (function), PROs, and patient preference information to enable deep patient phenotyping and inform clinical decision-making on personalized treatments in order to improve outcomes.
This effort will involve software and hardware development to enable data collection, analysis, and visualization in clinical settings. Technology development effort will be done in partnership with Switchbox Inc. (software strategy) and Priority Designs Inc. (regulatory strategy).
The specific aims for UH2 phase are to:
1) Develop a digital health platform for collecting, analyzing, and reporting core CLBP metrics.
2) Conduct a feasibility study to test the clinical operability, usability, and utility of the prototype.
The specific aims for UH3 phase are to:
1) Optimize digital health platform for translation to clinical research use through BACPAC.
2) Validate the utility of the digital health platform to identify CLBP patient phenotypes and inform clinical decision-making on optimal treatment pathways for individual patients.
The outcome of this project will be a digital health platform with data to support regulatory submission for clinical use. At the end of this effort, we will have a validated tool for integration in clinical research studies supported by the BACPAC Consortium.
Chronic low back pain (CLBP) is a debilitating condition that affects millions of people globally. Despite increased utilization of interventions and rising medical costs, CLBP prevalence has continued to increase. This problem arises because CLBP is complex, heterogeneous, and current diagnostics and treatments rely primarily on subjective metrics and do not target all the multidimensional biopsychosocial mechanisms associated with CLBP.
Specifically, most diagnostics do not quantitatively consider patient functional measures. This multidisciplinary effort proposes to address this problem by developing and validating a digital health platform and provide meaningful data-driven metrics that enable an integrated approach to clinical evaluation and treatment of CLBP. This platform will facilitate the use of quantitative spinal motion metrics (function), PROs, and patient preference information to enable deep patient phenotyping and inform clinical decision-making on personalized treatments in order to improve outcomes.
This effort will involve software and hardware development to enable data collection, analysis, and visualization in clinical settings. Technology development effort will be done in partnership with Switchbox Inc. (software strategy) and Priority Designs Inc. (regulatory strategy).
The specific aims for UH2 phase are to:
1) Develop a digital health platform for collecting, analyzing, and reporting core CLBP metrics.
2) Conduct a feasibility study to test the clinical operability, usability, and utility of the prototype.
The specific aims for UH3 phase are to:
1) Optimize digital health platform for translation to clinical research use through BACPAC.
2) Validate the utility of the digital health platform to identify CLBP patient phenotypes and inform clinical decision-making on optimal treatment pathways for individual patients.
The outcome of this project will be a digital health platform with data to support regulatory submission for clinical use. At the end of this effort, we will have a validated tool for integration in clinical research studies supported by the BACPAC Consortium.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Place of Performance
Columbus,
Ohio
432101273
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/24 to 08/31/25 and the total obligations have increased 28% from $3,074,856 to $3,945,111.
Ohio State University was awarded
Spine Phenome Project: Personalized Medicine for CLBP
Cooperative Agreement UH3AR076729
worth $3,945,111
from the National Institute of Neurological Disorders and Stroke in September 2019 with work to be completed primarily in Columbus Ohio United States.
The grant
has a duration of 6 years and
was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs.
The Cooperative Agreement was awarded through grant opportunity HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 8/5/24
Period of Performance
9/26/19
Start Date
8/31/25
End Date
Funding Split
$3.9M
Federal Obligation
$0.0
Non-Federal Obligation
$3.9M
Total Obligated
Activity Timeline
Transaction History
Modifications to UH3AR076729
Additional Detail
Award ID FAIN
UH3AR076729
SAI Number
UH3AR076729-428850568
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NB00 NIH NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
Funding Office
75NQ00 NIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Awardee UEI
DLWBSLWAJWR1
Awardee CAGE
5QH98
Performance District
OH-03
Senators
Sherrod Brown
J.D. (James) Vance
J.D. (James) Vance
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) | Health research and training | Grants, subsidies, and contributions (41.0) | $512,222 | 59% |
Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $292,717 | 34% |
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Health and Human Services (075-0886) | Health research and training | Grants, subsidies, and contributions (41.0) | $65,316 | 8% |
Modified: 8/5/24